Table 2. Safety and AE with crizotinib.
Number (%) | |
---|---|
Adverse event | |
• Visual Hallucination | 01 (6.2%) |
• Anaemia | 02 (12.5%) |
• Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) |
03 (18.7%) |
• Neutropenia | 01 (6.2%) |
• Diarrhoea | 00 |
• QTc prolongation | 02 (12.5%) |
• Bradycardia | 01 (6.2%) |
• Renal insufficiency | 02 (12.5%) |
Drug interruptions | |
• Toxicity | 01 (6.2%) |
• Lack of compliance | 02 (12.5%) |
• Drug unrelated | 00 |
Dose reductions | 00 |